

GEORGE JOHN ALANGADEN, M.D.

OFFICE ADDRESS

Division of Infectious Diseases
3990 John R., Suite #5930
Detroit, MI, USA, 48201
Phone: (313) 745-7105
Fax: (313) 993-0302

EDUCATION

1975 Intermediate Science (Pre-Med), University of Bombay, India
1981 M.B.,B.S. Degree, University of Bombay, India
1984 M.D. Degree (Int. Med.), University of Bombay, India
1988 M.R.C.P Degree (Int. Med.), Royal College of Physicians, United Kingdom
1991 Board Certified (Int. Med.) The American Board of Internal Medicine
1994 Board Certified in Infectious Diseases. The American Board of Internal Medicine
2002 Board Recertified (Int. Med.) The American Board of Internal Medicine
2002 Board Recertified in Infectious Diseases. The American Board of Internal Medicine

TRAINING

1980-81 Internship, Goa Medical College Group of Hospitals, Panaji, Goa, India
1981-84 Residency in Internal Medicine, Goa Medical College Group of Hospitals, Panaji, Goa
1985-86 Senior House Officer, Internal Medicine, Prince Charles Hospital, Merthyr Tydfil, United Kingdom
1986-87 Senior House Officer, Internal Medicine, Walsgrave General Hospital, Coventry, United Kingdom
1987-89 Registrar, Integrated Medicine, Walsgrave General Hospital, Coventry, United Kingdom

Curriculum Vitae

1989-91 Residency in Internal Medicine, Wayne State University Affiliated Hospitals, Detroit, MI

1991-94 Fellowship in Infectious Diseases, Wayne State University Affiliated Hospitals, Detroit, MI

FACULTY APPOINTMENTS

1994-2001 Assistant Professor, Department of Internal Medicine, Division of Infectious Diseases. Wayne State University School of Medicine, Detroit, MI.

2001-Present Associate Professor, Department of Internal Medicine, Division of Infectious Diseases. Wayne State University School of Medicine, Detroit, MI.

HOSPITAL AND OTHER PROFESSIONAL APPOINTMENTS

1994-Present Staff Physician, Detroit Medical Center Hospitals and Karmanos Cancer Institute

2002-Present Chair, Infection Control and Epidemiology Harper University Hospital, Hutzel Women's Hospital, Michigan Orthopedic Specialty Hospital

2006-Present Chair Infection Control and Epidemiology, Karmanos Cancer Institute

MAJOR PROFESSIONAL SOCIETIES

Royal College of Physicians (U.K.) Member

American Society of Microbiology, Member

American College of Physicians, Associate

Immunocompromised Host Society, Member

Infectious Diseases Society of America, Member

Michigan Infectious Diseases Society, Member

LICENSURE AND BOARD CERTIFICATION

State of Michigan – License (4301055076)

1991 Board Certification in Internal Medicine. The American Board of Internal Medicine

1994 Board Certification in Infectious Diseases. The American Board of Internal Medicine

2002 Board Recertification in Internal Medicine. The American Board of Internal Medicine

2002 Board Recertification in Infectious Diseases. The American Board of Internal Medicine

AWARDS

Best Student First M.B.B.S., Class of 1976.

Wayne State University School of Medicine Teaching Award 1999

Wayne State University School of Medicine Teaching Award 2005

Best Doctors in America 2006

SERVICE ACTIVITY

Patient Care

Attending Physician at Detroit Medical Center Hospitals 1994- present.

Inpatient consultations in Infectious Diseases, Primary care service in General Internal Medicine and Outpatient Clinics in Infectious Diseases.

Protocol development for prevention and treatment of infections in Stem Cell Transplantation and Renal transplantation recipients 1998- Present.

Database development and review of all infections in renal/pancreas transplant recipients in conjunction with Renal Transplant Team HUH. 2003- present.

Hospital committees

Member of Medical Usage Evaluation (MUE) Committee at Veterans Administration Medical Center 1996.

Member Tuberculosis Advisory Committee 1996, at Veterans Administration Medical Center 1996.

Member of the Pharmacy and Therapeutics, Antimicrobial Subcommittee, DMC 1998-Present.

Member of Medical Usage Evaluation (MUE) Committee at Harper University Hospital 2002 – Present.

Member of the Pharmacy and Therapeutics, Antimicrobial Subcommittee, Karmanos Cancer Institute 2006-Present.

Member of the Hospital Performance Improvement Committee, Karmanos Cancer Institute 2006-Present.

Chair, Hospital Epidemiology and Infection Control Harper University Hospital, Karmanos Cancer Institute, Hutzel Hospital, The Michigan Orthopedic Specialty Hospital 2002 – Present.

Chair, Hospital Epidemiology and Infection Control Karmanos Cancer Institute 2006-Present.

Departmental activity

Member of the Infectious Diseases Quality Evaluation Committee at Harper Hospital.

Interviewing ID faculty applicants 2005.

Interviewing ID fellowship applicants 1996-Present.

Interviewing residency applicants 2003-2005.

Interviewing applicants for Chief of PCR laboratory DMC University Laboratories, 2003.

Member, Search Committee for Chief of Ambulatory Services University Internists 2003.

Member, Search Committee for Chief of Cardiology, University Internists 2003-2004.

Member, Department of Internal Medicine Budget Committee 2004 -2005.

Member, Department of Pathology Internal Review Committee. 2005-06

Member of the Professional Affairs Committee 2007

Community Service

Committee Member of the St. Thomas Aquinas Parish Health Ministry. 1997-present.

JOURNALS

Manuscripts reviewed

1. JAMA 1998.
2. Hospital Physician 1997-2002.
3. Submission and review of examination questions in the specialty of

4. Infectious Diseases for the American Board of Internal Medicine 1996-2006.
4. Clinical Infectious Diseases 1996-present.
5. Archives of Internal Medicine 1997-2003.
6. American Journal of Hematology 2003-present.
7. McMaster University Web-based Journal Rating 2003-Present.
8. Journal of Clinical Pathology 2004-Present.
9. European Journal of Pediatrics 2004
10. Mycoses 2006

OTHER

Participant in formulation of the USPHS/IDSA/ASBMT Guidelines for the prevention of opportunistic infections in bone marrow transplant patients. Centers for Disease Control and Prevention, Atlanta, Ga. Published in MMWR 2000;49:RR-10.

TEACHING ACTIVITY

Teaching Awards

Wayne State University School of Medicine Teaching Award 1999

Wayne State University School of Medicine Teaching Award 2005

Teaching Activity

- 1994-2001 Year III Medical Students Infectious Diseases Course 1994-2001.
1994-Present Year II Medical Students Microbiology Course.
1994-Present Medical Students Physical Diagnosis Course.
1994-Present Medical Residents and Infectious Diseases Fellows Didactics and Clinical Teaching.
1995-96 Medical Resident Research Trainee August-November.
1996-Present Research Mentor for Infectious Diseases Fellows.
1996-Present Mentor for medical residents research.
2001-Present MKSAP Board Review for Medical Residents, 2001-present.
1996-97-2003 Morning Report for Medical Residents at Harper Hospital.
1998-03 Morning Report for Medical Residents at Detroit Receiving Hospital.
1998-03 Morning Report for Yr III Medical Students at Detroit Receiving Hospital,
1995-Present Preceptorship for visiting Pharmaceutical trainees.
1997-Present Physician Assistant Infectious Diseases Course 1997-Present.
2004-06 Director of the ID Lecture Series (2004-2006).
(Organization and selection of topics and internal and external faculty for weekly ID lecture series).

2004-Present Curriculum development and course material for Infection Control and Epidemiology for Infectious Diseases Fellows 2004- present.

Teaching Presentations

OSCE WSU July 1999

Two month mini-fellowship in HIV-medicine for visiting physicians from India- July-August 1999.

Eight Annual Resident Research Day. Grading and judging of Abstracts 2000.

HIV infection and the ER physician. Curriculum development. June 2000-01.

Wayne State University ENT Basic Science Course. Fungi and Mycoses. Harper Hospital March 7th 2001.

Ambulatory Grand Rounds Department of Internal Medicine. Recent advances in Tuberculosis. April 17th, 2001.

Infectious Diseases Conference, August 18th, Crystal Mt., MI. Advances in the treatment of viral hepatitis (CME).

Infectious Diseases Conference, August 18th, Crystal Mt., MI. Common viral syndromes (CME).

Ambulatory Grand Rounds Department of Internal Medicine. Approach to infections in the immunocompromised host. October 16th, 2001.

Medicine Grand Rounds. Infections in patients with cancer. Goa Medical College. Panaji, Goa, India. January 11th 2002.

Internal Medicine Update Conference Update, WSU, Bay Harbor, MI. Diabetic foot infections. (CME).

Internal Medicine Update Conference, WSU, Bay Harbor, MI. Adult immunizations. (CME).

Ambulatory Grand Rounds Department of Internal Medicine. Foot Infections in diabetic patients. October 1, 2002 (CME)

Emergency Department Grand Rounds Beaumont Hospital. HIV infection and the ED physician, November 12, 2002.

Internal Medicine Grand Rounds. Robert Packard Hospital Sayre PA, December 6, 2002. Management of fungal infections in high-risk patients. (CME).

Infectious Diseases Symposium. 1st Annual International Medical Society Meeting “Advances in Medicine in the New Millennium”. January 3-5, 2003, Goa India. Approach to patients with pneumonia. (CME).

Infectious Diseases Workshop. 1st Annual International Medical Society Meeting “Advances in Medicine in the New Millennium”. January 3-5, 2003, Goa India. Antimicrobial resistance in Mycobacterium tuberculosis. (CME).

Grand rounds Internal Medicine. Herman Keifer Hospital, Detroit MI. February 20, 2003. Viral hepatitis.

Grand Rounds Internal Medicine. Hospital, Memorial Hospital Owosso, MI. May 28, 2003. Management of fungal infections. (CME).

Grand Rounds Internal Medicine. Lake Charles Memorial Hospital, Louisiana. July 15, 2003. Managing infections in patients with hematological malignancies. (CME).

Infectious Diseases, Lecture. Prioritizing patient care in the HIV infected patient. Chicago, IL. September 17, 2003. (CME).

Infectious Diseases, Lecture. Prioritizing patient care in the HIV infected patient. Birmingham, MI. September 17, 2003. (CME).

Internal Medicine Lecture Series. Pontiac Osteopathic Hospital. August 13, 2003. Neutropenic sepsis. (CME).

Infectious Diseases, Lecture. Prioritizing patient care in the HIV infected patient. Cleveland, OH. September 17, 2003. (CME).

Grand Rounds Internal Medicine. Provena United Samaritans Medical Center Danville, IL. September 19, 2003. Managing infections in patients with hematological malignancies. (CME).

Internal Medicine. Ambulatory Medicine Grand Rounds. Harper Hospital, October 2003, Detroit MI. Peer Education Project on Adult Immunization.

Infectious Diseases, ICAAC and IDSA Conference Update, Ritz Carlton, October 30, 2003. Non-HIV viral infections.

Symposium. Michigan Medical Society Annual Meeting, Troy, MI, November 7, 2003. New Antimicrobial Agents. (CME).

Internal Medicine Grand Rounds. St Mary's Hospital. Livonia, MI, December 3, 2003. Management of Infection in patients with malignancies. (CME).

Infectious Diseases Grand Rounds. Henry Ford Hospital, Detroit MI. December 10, 2003. Management of Ventilator-associated pneumonia. (CME).

Symposium, HIV Infection Issues for the Practicing Physician. 2nd Annual Asian American International Medical Society Meeting "Healthcare – a Global Perspective". January 2-4, 2004 Florida USA. (CME).

CME Presentation. Emerging Infectious Diseases. 2nd Annual Asian American International Medical Society Meeting "Healthcare – a Global Perspective". January 2-4, 2004 Florida USA. (CME).

Infectious Diseases Update: Emerging respiratory infections. Association of Kerala Medical Graduates (AKMG) Silver Jubilee CME Program. July 16, 2004. Dearborn MI (CME).

Internal Medicine Grand rounds. Management of Infections in Cancer Patients. January 6, Tulsa OK (CME).

Resident Lecture Series. Infections in patients with hematologic malignancies. January 20, 2004. Sinai Grace Hospital, Detroit MI.

Lecture Series Renal Transplant Nephrology. CMV Infections in the transplant recipient. February 19, 2004. Harper University Hospital.

Lecture Series in Infectious Diseases. Physician assistants training program. March 8, 2004. Appelbaum Allied Sciences, Detroit MI.

Symposium on Infectious Diseases: Management of febrile neutropenia. March 13, 2004 St John's Hospital, Detroit MI. (CME).

Internal Medicine Grand rounds. Management of infections in patients with hematologic malignancies. March 25 2004, St Vincent's Hospital Cleveland, OH. (CME).

Internal Medicine Grand rounds. Update on immunization. March 29, 2004, Botsford Hospital, Detroit MI. (CME).

Internal Medicine Grand rounds. Management of infections in patients with malignancies. April 14, 2004, Robinson Memorial Hospital, Ravenna OH. (CME).

Internal Medicine Grand rounds. Management of infections in cancer patients with neutropenia. April 20, 2004, Crittendon Hospital, Rochester MI. (CME).

Internal Medicine Grand rounds. Management of infections in patients with malignancies. July 9, 2004, Midwestern Cancer Hospital, Zion IL (CME).

Department of Emergency Medicine Conference Series – Current management of Tuberculosis. September 13, 2004 Detroit Receiving Hospital, Detroit MI.

Infectious diseases Update for the Practicing Physician - Tuberculosis. September 22, 2004 Providence Hospital, Southfield MI (CME).

Influenza Update. Beaumont family Practice Center, October 28, 2004, Troy MI. (CME).

Resident Lecture Series, Tuberculosis, Detroit Hospital, August 18, 2005.

Adult Immunization Lecture. Eugene Applebaum College of Pharmacy, WSU February 17, 2005. (CME)

Lecture Series in Infectious Diseases. Infections in Immunocompromised Hosts. Physician assistants training program, Appelbaum Allied Sciences WSU, Detroit MI, March 7, 2005.

ESBLs and clinical significance. Vascular Surgery Rounds University Hospital of Cleveland March 8, 2005.

Facility acquired pneumonia. Invited Lecture, Michigan Society of Infection Control Annual Spring Meeting, Lansing, March 15, 2005. (CME)

Mathematics and Medicine. Invited lecture, Indus Center of Academic Excellence, 10th Anniversary Banquet, Farmington, MI, March 19, 2005.

Resident Lecture Series, Meningitis Harper Hospital, August 18, 2005.

Immunization update. Henry Ford Medical Group, Sterling Heights MI, September 15, 2005. (CME)

Moderator, Roundtable Conference Fungal Infections, Tampa, Florida, October 20, 2005.(CME).

Internal Medicine Rounds, Garden City Hospital, Garden City, MI. Hospital-Acquired Pneumonia. October 21, 2005.

Ambulatory Grand rounds. Approach to Infections in Immunocompromised Hosts. Harper Hospital, November 15, 2005. (CME).

Grand Rounds, Battle Creek Health System, Current Management of Fungal Infections. Battle Creek MI, June 16, 2006 (CME)

Grand Rounds St Mary's Hospital, Case Studies in Fungal Infections. July 7, 2006, Livonia MI. (CME).

Symposium. Annual Meeting Wayne State University School of Pharmacy. Update on Fungal Infections. September 2006, Detroit MI (CME).

Symposium. Michigan Medical Society Annual Meeting, What's New in Infectious Diseases? October 26, 2006. Troy, MI. (CME).

Grand Rounds, Family Medicine. New Vaccines and Immunization update. November 26, 2006. Bon Secour Hospital Grosse Pointe MI. (CME).

Surgery Rounds, Vascular Surgery Wayne State University. Surgical Site Infections and Emerging Pathogens. February 26. Harper Hospital Detroit MI.

Radiology Rounds Interventional Radiology. Antibiotic Prophylaxis in Interventional Radiology. April 26, 2007, Harper Hospital Detroit MI.

Symposium (via videoconference). Critical Care International Conference. Recent Advances in the Diagnosis and management of Tuberculosis. King Faisal Hospital, Saudia Arabia May 7, 2007.

Ambulatory Grand Rounds Wayne State University. Newer Vaccines and adult vaccination. May 15, 2007. Detroit, MI. (CME).

Grand Rounds, Goa Medical College, Recent Advances in Infectious Diseases. July 12, 2007. Goa Medical College Panaji, Goa India.

Teaching Activity Other

Chief Organizer, Program and curriculum development, 1st Annual Asian American International Medical Society Meeting “Advances in Medicine in the New Millennium”. January 3-5, 2003, Goa India.

Program and curriculum development and organizer of the 2nd Annual Asian American International Medical Society Meeting “Healthcare – a Global Perspective”. January 2-4, Florida USA.

Program and curriculum development and organizer of the 3rd Annual Asian American International Medical Society Meeting “Medical Care and Education for the Global Village”. January 2-5, 2005, Colombo, Sri Lanka. Cancelled following the tsunami tragedy. Rescheduled for August 2007-08.

GRANT SUPPORT

Department of Medicine Research Committee (Harper Staff Trust Fund). Cloning and expression of the β -lactamase of *Mycobacterium tuberculosis*. Total grant \$3000.00 for the period 7/1/92 to 6/30/93.

NATIONAL AND LOCAL CLINICAL RESEARCH PROTOCOLS

1. 1995 Sequus Pharmaceuticals - \$70,000 – “A double-blind, randomized comparison of Amphotericin B and Fluconazole in the treatment of invasive aspergillosis”. Coinvestigator.
2. 1995 Glaxo Wellcome - \$67,415 – “An open-label, pilot study to estimate the effect on patient survival and the safety of CMV prophylaxis with IV Acyclovir followed by Valacyclovir Hydrochloride or Ganciclovir in allogeneic bone marrow transplant recipients”. Coinvestigator
3. 1996 Sequus Pharmaceuticals - \$30,000 – “A double-blind randomized study comparing Amphotericin B colloidal dispersion and amphotericin B in the treatment of febrile neutropenic patients failing broad spectrum antibacterial therapy”. Coinvestigator.

4. 1996 Pfizer Pharmaceuticals - \$65,300 – “A multicenter, randomized, double-blind, active-controlled phase I study to investigate the safety, tolerance and pharmacokinetics of three increasing oral doses of voriconazole in patients with hematologic malignancies/conditions, solid tumors or autologous bone marrow transplantation at risk for aspergillosis”. Coinvestigator.
5. 1996 Janssen Research Foundation - \$97,500 – “A multicenter randomized, trial of fluconazole versus itraconazole for the prevention of fungal infections in allogeneic bone marrow transplant patients”. Coinvestigator.
6. 1997 Immunex - \$56,000 – “A phase II/III randomized, double-blind, placebo-controlled trial of recombinant human granulocyte-macrophage colony-stimulating factor (rhu GM-CSF) used to prevent invasive fungal infection in patients with graft versus host disease (GVHD)”. Coinvestigator.
7. 1997 “Study of the clinical experience and compassionate use of intravenous ribavirin in bone marrow transplant recipients with life-threatening viral infections”. Initiated the protocol and Primary investigator.
8. 1997 “Study of the outpatient management of febrile episodes in “low-risk” neutropenic patients with cancer”. Coinvestigator.
9. 1997 Pfizer Pharmaceuticals - \$63,425 – “An open randomized comparative multicenter study of the efficacy, safety and toleration of voriconazole versus amphotericin B followed by other licensed antifungal therapy in the treatment of acute invasive aspergillosis in immunocompromised patients”. Co-primary investigator.
10. 1997 Pfizer Pharmaceuticals - \$63,425 – “An open label non-comparative multicenter phase III trial of the efficacy, safety and toleration of voriconazole in the primary or secondary treatment of invasive fungal infections”. Co-primary investigator.
11. 1998 Pfizer Pharmaceuticals -\$116,384 – “Randomized open-label multicenter study of Voriconazole versus Ambisome for empiric antifungal therapy in immunocompromised patients with persistent fever and neutropenia” (Protocol #150-663). Co-primary investigator.
12. 1999 Fujisawa Pharmaceuticals “Phase I/II study to determine the maximum tolerated dose and pharmacokinetics of FK463 in combination with fluconazole for the prophylaxis of fungal infections in adult patients undergoing an autologous bone marrow or peripheral stem cell transplant”. (Protocol # 97-0-041). Coinvestigator.
13. 1999 Schering-Plough Research Institute - \$90,000 – “A phase III randomized double-blind (double-dummy) study of the safety tolerance and efficacy of SCH 56592 vs fluconazole in the prophylaxis of invasive fungal infections in high-risk recipients of allogeneic progenitor cell transplantation with graft-vs-host disease”. Coinvestigator.
14. 2000 2001 Schering-Plough Research Institute -\$1500- “Phase II study of the safety, tolerance and efficacy of Ziracin in patients with gram-positive infection” (Protocol #98-125). Primary investigator.
15. 2000-2001 Fujisawa Pharmaceuticals - \$80,000 – “Phase III randomized double-blind comparative trial of FK463 versus fluconazole for the prophylaxis of fungal infections in patients undergoing a hematopoietic stem cell transplantation”. Co-primary investigator.

16. 2000 IntraBiotics Pharmaceuticals - \$120,000 – Phase III randomized placebo-controlled double-blind multicenter efficacy and safety study of ramoplanin and placebo in neutropenic oncology patients identified as asymptomatic carriers of vancomycin-resistant enterococcus (VRE)”. Primary investigator.
17. 2000. Pharmacia and Upjohn -\$150,000 - Protocol 766-INF-0026-113 Linezolid IV or PO compared to Unasyn In or Augmentin PO for the treatment of patients with diabetic foot infections – a randomized, open-label phase IV clinical trial. Co-primary investigator.
18. 2000 Schering-Plough Research Institute -\$90,000 - #C98-316-15 Phase III randomized, double-blind (double-dummy) study of the safety, tolerance and efficacy of SCH 56592 vs fluconazole in the prophylaxis of invasive fungal infections in high-risk recipients of allogeneic stem cell transplants. Co-primary investigator.
19. 2001 Cubist Pharmaceuticals - \$162,000 –Protocol #DAP-VRE-00-07 A randomized, double-blind, double dummy, phase III comparative study of Cidecin (daptomycin) and Zyvox (linezolid) in the treatment of hospitalized adults with suspected vancomycin-resistant enterococcal infections. Co-primary investigator.
20. 2002 Fujisawa Study - \$32,500 – A Phase II, Open Label, Non-comparative Trial of Micafungin (FK 4630 in Combination with AmBisome as First-line Therapy in the Treatment of Invasive Aspergillosis. Co-investigator.
21. 2003 – 2005 Schering - \$66,000 – A Randomized Controlled Trial of Posaconazole (SCH 56592) vs. Standard Azole Therapy for the Prevention of Invasive Fungal Infections Among High-Risk Neutropenic Patients. Co-Investigator.
22. 2003 Merck – A multicenter open, noncomparative study to estimate the safety, tolerability, and efficacy of MK-0991 in combination with amphotericin B, lipid formulations of amphotericin B, or azoles in the treatment of invasive aspergillus infections in adults who are refractory to or intolerant of standard therapy. Co-investigator.
23. 2003 Genome Therapeutic Co. – \$27,000 - Protocol # GTC-894-204. A phase II randomized, open label multicenter trial of ramoplanin versus vancomycin for the treatment of *Clostridium difficile* associated diarrhea. Primary Investigator
24. 2004 -2005 ViroPharma Inc. – Maribavir/Protocol 1263-200. A randomized double-blind, placebo-controlled dose-ranging study to assess safety, tolerability, and prophylactic anti-cytomegalic activity of Marabavir in recipients of allogeneic stem-cell transplants. Primary Investigator.
25. 2005-2006. NIAID/Bacterial and Mycoses Study Group (BAMSG) - \$145,000 - Strategies to reduce transmission of antimicrobial resistant bacteria in intensive care units (STAR*ICU) trial. Primary Investigator.
26. 2005-2006 Cubist/Westat. CUBICIN Outcomes Registry and Experience (CORE) for the treatment of serious Gram-positive infections - \$6,000. Primary Investigator.
27. 2006 ViroPharma Inc. 2006-113 A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Prophylactic Use of Maribavir for the Prevention of Cytomegalovirus Disease in Recipients of Allogeneic Stem Cell Transplants. Primary Investigator.

28. 2006 Optimer Pharmaceuticals Protocol 2006-074: A Multi-National, Multi-Center, Double-Blind, Randomized, Parallel Group Study to Compare the Safety and Efficacy of 200 mg PAR-101 Taken q12 hrs with 125 mg Vancomycin Taken q 6 hrs for Ten Days in Subjects with Clostridium Difficile-Associated Diarrhea. Primary Investigator.
29. Schering Plough - \$41,969 -Open-label, Limited Access Protocol of Posaconazole in Invasive Fungal Infections. (Co-investigator).
30. Vical Inc.- \$45,788- A Phase 2 Clinical Trial to Evaluate the Safety, Immunogenicity and Clinical Benefit of a CMV Immunotherapeutic Vaccine in Donors and Seropositive Recipients Undergoing Allogeneic, Matched Related Hematopoietic Cell Transplant (HCT) (Co-Investigator).
31. Astellas Pharma US, Inc - A Double-Blind, Randomized Controlled Trial of Voriconazole (Vfend®) plus Micafungin (Mycamine™) versus Voriconazole plus Placebo Equivalent in the Treatment of Patients with Proven or Probable Invasive Aspergillosis. (Co-Investigator).

Local Investigator initiated funded protocols

32. 2001 Bayer Pharmaceutical Division - \$10,000 - “Surveillance of antimicrobial susceptibility patterns among bacterial pathogens isolated from bloodstream infections in patients at a large cancer institute year 2000. Initiated the protocol and Primary investigator.
33. 2002 Merck Pharmaceutical Division - \$10,000 “Surveillance of antimicrobial susceptibility patterns among bacterial pathogens isolated from bloodstream infections in patients at a large cancer institute year 2001. Initiated the protocol and Primary investigator.
34. 2003 Wyeth Pharmaceutical Division - \$10,000 “Surveillance of antimicrobial susceptibility patterns among bacterial pathogens isolated from bloodstream infections in patients at a large cancer institute year 2001. Initiated the protocol and Primary investigator.
35. 2003 Internal Funding Protocol # A 03-02-03 Thigh infection model in mice for testing the efficacy of various novel antibiotics. Primary Investigator.
36. 2004-2006 Elan Pharmaceutical - \$25,000 “Comparative efficacy of cefepime and other antibiotics against ESBL producing strains of Escherichia coli and Klebsiella pneumoniae in granulocytic mice”.
37. 2005-2006 OrthoMcNeil – \$25,000 “In vivo efficacy of levofloxacin compared to ciprofloxacin for the treatment of disseminated infection caused by clinical isolates of *Pseudomonas aeruginosa* in granulocytic mice”.

SCHOLARLY ACTIVITY

*Trainee supervision

PUBLICATIONS:

Original observations in peer reviewed journals

1. Alangaden G.J., Chandrasekar P.H., Bailey E. Khaliq Y. Antifungal prophylaxis with low dose fluconazole prophylaxis during bone marrow transplantation. Bone Marrow Transplantation. 1994, 14:919-924 .
2. Alangaden G., Manavathu E., Vakulenko S., Zvonok N., Lerner S. A Characterization of fluoroquinolone-resistant mutant strains of *Mycobacterium tuberculosis* selected in the laboratory and isolated from patients. Antimicrobi. Agents and Chemother. 1995, 39:1700-03
3. Manavathu E. K., Alangaden G., Lerner S. A comparative study of the microbroth and macrobroth dilution techniques for the determination of the in vitro susceptibility of *Aspergillus fumigatus*. Can. J. Microbiol.1996, 42:960-964
4. Manavathu E.K., Vashishta S.C., Alangaden G.J. In vitro antifungal activity of some Mannich bases of conjugated styryl ketones. Can. J of Microbiol.1998;44:74-79
5. Manavathu E.K., Alangaden G.J., Chandrasekar P.H. In vitro isolation and antifungal susceptibility of amphotericin B-resistant mutants of *Aspergillus fumigatus*. J Antimicrob Chemother 1998;41:615-619.
6. Alangaden G., Kreiswirth B., Manavathu E., Lerner S. A Mechanism of kanamycin and amikacin resistance in *Mycobacterium tuberculosis*. Antimicrob. Agents and Chemother. 1998;42:1295-97.
7. Manavathu E.K., Alangaden G.J., Chandrasekar P.H. In vitro isolation and antifungal susceptibility of amphotericin B-resistant mutants of *Aspergillus fumigatus*. J. Antimicrob. Chemother. 1998;41,615-619.
8. *Hidalgo J.A., Alangaden G.J., Elliott D, et al. Fungal endophthalmitis diagnosis by detection of *Candida albicans* DNA in intraocular fluid using a species-specific PCR assay. J Infect Dis. 2000;181:1198-201.
9. Chandrasekar PH, Alangaden G, Manavathu E. Aspergillus - A rising problem in tertiary care hospitals? Clin Infect Dis. 2000;30:984-5.
10. *Kanno M, Chandrasekar PH, Bentley G, Alangaden GJ. Disseminated cytomegalovirus disease in hosts without Acquired Immunodeficiency Syndrome and without organ transplant. Clin Infect Dis. 2001;32:313-316.
11. *Chandrasekar PH, Abraham OC, Klein J, Alangaden GJ, Chalasani G, Cassells, L, Dansey R, Abella S, Karanes C, Peters W, Baynes R. Low infectious morbidity following intensive chemotherapy and autologous peripheral blood progenitor cell transplantation in the outpatient setting for women with breast cancer. Clin Infect Dis. 2001;32:546-551.
12. *Moosa MYS, Alangaden GJ, Manavathu EK and Chandrasekar PH. Resistance of Amphotericin B does not emerge during treatment for invasive aspergillosis. J Antmicrob Chemother 2002;209-213, 2002.
13. *Alangaden GJ, M. Wahiduzzaman, Pranatharthi H. Chandrasekar and the Bone Marrow Transplant Group. Aspergillosis: The most common community-acquired pneumonia with gram-negative Bacilli as copathogens in stem cell transplant recipients with graft-versus-host disease. Clin Infect Dis. 2002 Sep 15;35(6):659-64.

14. *Pulimood S, Ganesan L, Alangaden G, Chandrasekar P. Polymicrobial candidemia. *Diag Microbiol Infect Dis.* 2002;44:353-57.
15. Manavathu EK, Alangaden GJ, Chandrasekar PH. Differential activity of triazoles in two-drug combinations with the echinocandin caspofungin against *Aspergillus fumigatus*. *J Antimicrob Chemother.* 2003 Jun; 51(6): 1423-5. Epub 2003 Apr 25.
16. *Varanasi NL, Baskaran I, Alangaden GJ, Chandrasekar PH and Manavathu EK. Novel Effect of Voriconazole on Conidiation of *Aspergillus* species. *Int J Antimicrob Agents* 2004;23:72-9.
17. *Ganesan LT, Manavathu EK, Curtight JL, Alangaden GJ, Chandrasekar PH. In vitro activity of Nikkomycin Z alone and in combination with polyenes, triazoles or echinocandins against *Aspergillus fumigatus*. *Clin Microbiol. Infection.* 2004;10:961-966.
18. Alangaden GJ, MD, William J Brown, Ph.D, Prantharthi H Chandrasekar MD. Recognition of Misdiagnosed Tuberculosis in a Bone Marrow Transplant Recipient Leads to Identification of "Pseudo-tuberculosis" due to Laboratory Contamination. *Infect. Dis Clin Pract.* 2004;12:328-34.
19. *Wadei H, Alangaden GJ, Sillix DH, El-Amm JM, Gruber SA, West MS, Granger DK, Garnick J, Chandrasekar P, Migdal SD, Haririarn A. West Nile Virus encephalitis: an emerging disease in renal transplant recipients. *Clin Transplant* 2004. 18:753-58.
20. Gruber SA, Garnick J, Morawski K, Sillix DH, West MS, Granger DK, Jose M. El-Amm, Alangaden GJ, Chandrasekar PH, Haririan A. Cytomegalovirus Prophylaxis with Valganciclovir in African-American Renal Allograft Recipients Based on Donor/Recipient Serostatus. *Clin Transplant.* 2005 Apr;19(2):273-8.
21. Alangaden GJ, Thyagarajan R, Gruber SA, Morawski K, Garnick J, El-Amm JM, West MS, Sillix DH, Chandrasekar PH, Haririan A. Infectious complications after kidney transplantation: current epidemiology and associated risk factors. *Clin Transplant.* 2006 Jul-Aug;20(4):401-9.
22. Haririan A, Morawski K, West MS, El-Amm JM, Doshi MD, Cincotta E, Alangaden GJ, Chandrasekar PH, Gruber SA. Sirolimus Exposure During the Early Posttransplant Period Reduces the Risk of CMV Infection Relative to Tacrolimus in Renal Allograft Recipients. *Clin Transplant.* 2006 Jul-Aug;20(4):401-9.
23. Narreddy S, Mellon-Reppen S, Abidi M, Klein JL, Peres E, Heilbrun LK, Smith D, Alangaden GJ, Chandrasekar PH. Non-bacterial infections in allogeneic non-myeloablative stem cell transplant recipients. *Transplant. Infect Dis.* 2007, 9(1);3-10.
24. Afonso NM, Gunasena S, Galla K, Podzorski R, Chandrasekar PH, Alangaden GJ. Appropriate Use of Polymerase Chain Reaction for Detection of Herpes Simplex Virus -2 in Cerebrospinal Fluid of Patients at an Inner-City Hospital. *Diagnostic Microbiology & Infectious Disease* 2007, 57(3);309-13.

Original observations resulting from multicenter study participation

1. Walsh TJ, Pappas P, Winston DJ, et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. *N Engl J Med* 2002;346:225-234 34.

Review Articles

1. Chandrasekar P., Alangaden G.J. Newer beta-lactam antibiotics. *Current Opinion in Infectious Diseases*.1996, 9:391-97
2. Alangaden G.J., Lerner S. Clinical Updates in Infectious Diseases: Overview of Antibiotic Resistance. *Clinical Updates; IV: (1): 1-4*. National Foundation for Infectious Diseases.
3. Alangaden G., Lerner S. Clinical use of fluoroquinolones for the treatment of mycobacterial diseases. *Clin. Infect. Dis.* 1997;25:1213-21.
4. Chandrasekhar P., Alangaden G.J. Herpes-associated erythema multiforme. *Infectious Diseases in Clinical Practice*. 1998;7:295-97.
5. Alangaden G.J. Miscellaneous Fungi. *Current Treatment Options in Infectious Diseases* 2000; 2:499-506.
6. Alangaden G.J. Tuberculosis - Review Questions-Self Assessment in Infectious Diseases. *Hospital Physician*. 2002; 28:37-38.
7. *Varon N, Alangaden J. Emerging trends in infections among renal transplant recipients. *Expert Rev. Anti-Infect Ther.* 2004;2:95-109.
8. Alangaden G.J. Management of fever in cancer patients with neutropenia - Review Questions-Self Assessment in Infectious Diseases. *Hospital Physician*. 2004.

Book Chapters

1. Alangaden G.J. Leptospirosis. In: Humes HD, ed. *Kelly's Textbook of Internal Medicine* 4th ed. Lippincott Williams & Wilkins. 2000.
2. Hidalgo J, Alangaden G.J. Potts's Disease (Tuberculous spondylitis). In *Emedicine Online Internal Medicine Textbook (www.emedicine.com)*.2001.
3. Alangaden G.J. Infections in neutropenic cancer patients. In Kruse JA, Fink MP, ed. *Saunders Manual of Critical Care* 1st ed. Elsevier Science 2003.
4. Alangaden G. J. Joint infections and Infections of prosthetic joints. In McCue JD, ed *Infectious Diseases. Handbook of Infectious Diseases In a Page*. 1st ed. Lippincott Williams & Wilkins 2007.
5. Alangaden G.J., Chandrasekar P.H. Infections in Kidney, Pancreas and Intestinal Transplant Recipients. In Byungse Suh, ed. *Cumitech Series – American Society of Microbiology* 2007 (In press).

Case Reviews in peer-reviewed journals

1. *Bazzi M.N., Alangaden G.J., Nunlee W., Lubik M. Colonic phytobezoar due to popcorn kernels. *Resident and Staff Physician*, February 1992; 127-133.
2. *Afonso L., Dihenkar J., Alangaden G.J. Leptospirosis: an unusual cause of fever, jaundice and renal failure. *Infectious Diseases in Clinical Practice*. 1997, 6:203-05.
3. *Aouad A., Alangaden G.J. Photo quiz / Arcanum. *Clinical Infectious Diseases*. 1998;26:1439.

4. *Samuel J, Alangaden G.J, and Chandrasekar PH. Cervical adenitis due to *Mycobacterium fortuitum* in a patient with AIDS. Infect Dis Clin Pract. 2000;9:221-222.
5. *Nelia M Afonso, Hymavathy Jasti, George J Alangaden, Tuberculosis of the ribs presenting as bilateral pseudogynecomastia. Infect. Dis Clin Pract. 2001;10:125-26.

Abstracts presented at international, national and local meetings

1. Bazzi M.N., Alangaden G. Psoas abscess in a patient with decubitus ulcers. American College of Physicians, Michigan Scientific Meeting, September, 1991, Traverse City, MI.
2. Bazzi M.N., Alangaden G. Positive chest CT scan, normal X-ray Abstr. American College of Physicians, Michigan Scientific Meeting, September, 1991, Traverse City, MI.
3. Alangaden G., Shearer C., Chandrasekar P. Fungemia among bone marrow transplant recipients, 1989-1991. Effect of low dose fluconazole prophylaxis. Abstr 622. In the Program and abstracts of The 32nd
4. Interscience Conference on Antimicrobial Agents and Chemotherapy, October 11-14, 1992: Anaheim, California.
5. Alangaden G., Manavathu E., Lerner S. Selection of fluoroquinolone resistance in *M. tuberculosis*. Abstr 112, pg. 20-A). In the Program and abstracts of The 31st Annual Meeting of The Infectious Diseases Society of America, October 16-18, 1993: New Orleans, Louisiana
6. Alangaden G., Lerner S. Manavathu E. Activity of ciprofloxacin, Ofloxacin, Sparfloxacin, and Five Investigational Fluoroquinolones against Quinolone-Resistant Strains of *M. tuberculosis*. Abstract. Fifth International Symposium on New Quinolones, August 25-27, 1994. Singapore.
7. Alangaden G., Manavathu E., Lerner S. Susceptibility of Quinolone-Resistant Strains of *Mycobacterium tuberculosis* to Ciprofloxacin, ofloxacin, Sparfloxacin, and Five Investigational Fluoroquinolones. Abstr 176. In the Program and abstracts of The 32nd Annual Meeting, of The Infectious Diseases Society of America October 7-9,1994, Orlando.
8. Manavathu E., Alangaden G.J., Lerner S. A comparative study of the micro- and macrobroth dilution techniques for the determination of *in vitro* susceptibility of *Aspergillus fumigatus*. Abstr C-356. In the Program and abstracts of, 95th general Meeting, American Society for Microbiology, May 21-25 1995, Washington, DC.
9. Manavathu E., Alangaden G.J., Lerner S. Selection and characterization of azole-resistant mutants of *Aspergillus fumigatus*. Abstr A-36. In the Program and abstracts of 95th general Meeting, American Society for Microbiology, May 21-25 1995, Washington, DC.
10. Manavathu E., Alangaden G.J., Lerner S. Isolation and characterization of itraconazole-resistant mutants of *Aspergillus fumigatus*. Abstr C101. In the Program and abstracts of The 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 17-20 1995, San Francisco.
11. *Alangaden G., Igno F., Zvonok N., Lerner A. Mechanism(s) of amikacin and streptomycin resistance *M. tuberculosis*. Abstr U77. In the Program and abstracts of The

- 96th General Meeting of the American Society for Microbiology, May 19-23, 1996, New Orleans.
12. Manavathu E., Alangaden G.J., Vashishtha S., Dimmock J. Antifungal activity of a new class of conjugated styryl ketones. Abstr A81 *In the Program and abstracts of The 96th General Meeting of the American Society for Microbiology, May 19-23, 1996, New Orleans.*
 13. *Stokes D., Ahmed S., Alangaden G.J. Cutaneous norcardiosis in an immunocompromised host. Annual Meeting of the American College of Physicians, Michigan Chapter, 1996.
 14. *El-Menini I., Aouad A., Alangaden G.J.. A case of *Mycobacterium bovis* after intravesicular therapy with Bacillus Calmette Guerin - A literature review. Annual Meeting of the American College of Physicians Michigan Chapter, 1996.
 15. Manavathu E., Alangaden G., Vashishtha S., Dimmock J. Effect of a new class of conjugated styryl ketones on fungi. Abstr F184. *In the Program and abstracts of The 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 15-18 1996, New Orleans.*
 16. *Alangaden G.J., Igno F., Zvonok N., Manavathu E., Lerner S. Mechanism(s) of kanamycin and amikacin resistance in *M. tuberculosis*. Abstr C136. *In the Program and Abstracts of The 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 15-18 1996, New Orleans.*
 17. *Alangaden G.J., Kreiswirth B.K., Aouad A., Khetarpal M., Moghazeh S., Manavathu E.K., Lerner S.A. Mechanism of high-level kanamycin and amikacin resistance in clinical isolates of *Mycobacterium tuberculosis*. Abstr C3. *In the Program and abstracts of The 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 28-October 1, 1997, Toronto.*
 18. *Stokes D., Shree N., Fairfax M., Alangaden G.J. Cryptococcal disease in patients not infected with HIV. Abstr 700. *In the Program and Abstracts of The 35th Annual Meeting of the Infectious Diseases Society of America, September 13-16, 1997, San Francisco.*
 19. Pulimood S., Alangaden G.J., Chandrasekar. Candidemia due to multiple species at a tertiary care institution. Abstr 092. *In the Program and abstracts of the 10th International Symposium on Infections in the Immunocompromised Host, June 21-24, 1998, Davos, Switzerland.*
 20. *Kumar A., Alangaden G.J., Chandrasekhar P.H. and the BMT team. Significance of *aspergillus* in clinical specimens from cancer patients at a tertiary care center. Abstr 086. *In the Program and abstracts of the 10th International Symposium on Infections in the Immunocompromised Host, June 21-24, 1998, Davos, Switzerland.*
 21. Pulimood S., Alangaden G.J., Chandrasekar. Changing epidemiology of candidemia at a tertiary care institution. Abstr 093. *In the Program and abstracts of the 10th International Symposium on Infections in the Immunocompromised Host, June 21-24, 1998, Davos, Switzerland.*
 22. *Mettassebia K., Chandrasekar P.H., Alangaden G.J. Cytomegalovirus disease in non-transplant recipients and non-HIV patients. Abstr 520. *In the Abstracts of the IDSA 36th Annual Meeting, November 12-15, Denver Colorado. Clin Infect Dis. 1998;27:1019.*

23. *Hidalgo JA, Alangaden G.J., Atkins RA, Abrams GW, Elliott D, Puklin J, Chandrasekar PH, Vasquez JA. Diagnosis of fungal endophthalmitis by detection of *Candida albicans* DNA in vitreous specimens using a species-specific PCR. *In the Abstracts of the IDSA 37th Annual Meeting, November 18-21, Philadelphia, Pennsylvania. Clin Infect Dis. 1999;29:968.*
24. *Wahiduzzaman M, Chandrasekar PH, Alangaden GJ. High frequency of Gram-negative pneumonia in Bone Marrow Transplant/ Stem Cell Transplant (BMT) recipients with graft-vs-host disease (GVHD) and pulmonary aspergillosis. *In the Abstracts of the IDSA 37th Annual Meeting, November 18-21, Philadelphia, Pennsylvania. Clin Infect Dis. 1999;29:1014.*
25. *Jamma K, Chandrasekar PH, Karanes C, Klein J, Cassells L, Dansey R, Abella S, Peters W, Baynes R, Alangaden GJ. Spectrum of *C. difficile* associated diarrhea in Stem Cell transplant recipients. *In the Abstracts (Abstract no 053) of the Immunocompromised Host Society 11th Annual Meeting, June 18-21 2000, Halifax Nova Scotia.*
26. Chilukuri S, Alangaden GJ, Karanes C, Klein J, Cassells L, Dansey R, Abella S, Peters W, Baynes R, Chandrasekar PH. Antifungal chemoprophylaxis in hematopoietic stem cell transplantation: an international survey. *In the Abstracts of the Immunocompromised Host Society 11th Annual Meeting, June 18-21, Halifax Nova Scotia.*
27. Alangaden G.J, Thompson E, Yoon S, Akins R, Chandrasekar P, Vazquez J. Diagnosis of invasive fungal infections by detection of fungal DNA in clinical specimens using a species-specific PCR. *In the Abstracts of the IDSA 38th Annual Meeting, September 7-10, New Orleans, Louisiana. Clin Infect Dis. 2000;31:260.*
28. *Alangaden G.J, Jamma K, Chandrasekar PH, Karanes C, Klein J, Cassells L, Dansey R, Abella S, Peters W, Baynes R. Clostridium difficile associated diarrhea during hematopoietic stem cell transplantation. *In the Abstracts of the IDSA 38th Annual Meeting, September 7-10, New Orleans, Louisiana. Clin Infect Dis. 2000;31:395.*
29. Manavathu EK, Bhaskaran I, Alangaden GJ and Chandrasekar PH. Molecular characterization of the P450-dependent lanosterol demethylase gene from clinical isolates of *Aspergillus fumigatus*. *IN: Programs and Abstracts of the 101st General Meeting of the American Society for Microbiology, May 20-24, 2001, Orlando, Florida, Abstract F-20.*
30. Manavathu EK, Bhaskaran I, Alangaden GJ and Chandrasekar PH. Differential susceptibility of itraconazole resistant *Aspergillus fumigatus* isolates to triazoles. *IN: Programs and Abstracts of the 101st General Meeting of the American Society for Microbiology, May 20-24, 2001, Orlando, Florida, Abstract A-18.*
31. *Varanasi NL, Bhaskaran I, Alangaden GJ, Chandrasekar PH and Manavathu EK. Novel effect of voriconazole on conidiation and pigmentation of *Aspergillus* species. *In Programs and Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, December 16-19, 2001, Chicago, Illinois, Abstract J-816.*
32. Manavathu EK, Bhaskaran I, Alangaden GJ, and Chandrasekar PH. Molecular characterization of laboratory isolates of *Aspergillus fumigatus* showing reduced susceptibility to voriconazole. *IN Programs and Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, December 16-19, 2001, Chicago, Illinois, Abstract J-817.*

33. *Varanasi NL, Bhaskaran I, Alangaden GJ, Thomas PA, Chandrasekar PH and Manavathu EK. In vitro susceptibility and azole resistance among clinical and laboratory-selected isolates of *Aspergillus flavus* obtained from three continents. IN Programs and Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, December 16-19, 2001, Chicago, Illinois, Abstract J-217
34. Chandrasekar PH, JL Cutright, GJ Alangaden and EK Manavathu. Invitro susceptibility of clinical isolates of *Aspergillus fumigatus* to conventional and lipid formulations of amphotericin B in 2-drug combination with caspofungin and micafungin. In Program and abstracts of the 12th International Symposium on Infections in the Immunocompromised Host, Bergen, Norway, 23-26 June 2002 published in International Journal of Infectious Diseases 2002;6:2S45
35. Alangaden GJ, EK Manavathu, JL Cutright and PH Chandrasekar. In vitro activity of ertapenem against gram-negative bacilli isolated from blood stream infections in cancer patients. In Program and abstracts of the 12th International Symposium on Infections in the Immunocompromised Host, Bergen, Norway, 23-26 June 2002 published in International Journal of Infectious Diseases 2002;6:2S61-2
36. Alangaden GJ, JL Cutright and PH Chandrasekar. Pathogens causing blood stream infections in hospitalized cancer patients, 200-2001. In Program and abstracts of the 12th International Symposium on Infections in the Immunocompromised Host, Bergen, Norway, 23-26 June 2002 published in International Journal of Infectious Diseases 2002;6:2S64.
37. *Singh S, R Stachler, GJ Alangaden. A case of probable diphtheria in a healthy Vaccinated US-born woman presenting with airway obstruction, carditis and neuritis. In Program and Abstracts of the 40th Annual Meeting of the IDSA, October 24-27, 2002. Chicago. Abstr no. 225.
38. *Alangaden GJ, P Robinson, K Preney, E Flanagan, T Lundstrom. Rotavirus infections among hematopoietic stem cell transplantation recipients. In Program and Abstracts of the 40th Annual Meeting of the IDSA, October 24-27, 2002. Chicago. Abstr no. 760.
39. *Afonso NM, S Gunasena. A Pagadala, R Podzorski, PH Chandrasekar, GJ Alangaden. Utility of polymerase chain reaction for the detection of Herpes Simplex Virus DNA in the cerebrospinal fluid in patients with suspected central nervous system infections. A case control study, 1997-2000. In Program and Abstracts of the 40th Annual Meeting of the IDSA, October 24-27, 2002. Chicago. Abstr no. 760.
40. Manavathu EK, Cutright JL, Alangaden GJ, Chandrasekar PH. In vitro activity of Nikkomycin Z in 2-drug combination with polyenes, triazoles and the echinocandin caspofungin against *Aspergillus fumigatus*. In Programs and Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, California, September 27-30, 2002.
41. Manavathu EK, Alangaden GJ, Chandrasekar PH. Differential activity of triazoles in 2-drug combination with the echinocandin caspofungin against *Aspergillus fumigatus*. In Programs and Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego California September 27-30, 2002.

42. Manavathu E, Bhaskaran I, Krishnan S, Alangaden GJ, Chandrasekar PH. Cytochrome P450 14-alpha-sterol demethylase mutation dependent triazole cross-resistance in *Aspergillus fumigatus*. In Programs and Abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Illinois, September 14-17, 2003. Abs# M-471.
43. Manavathu E, Espinel-Ingroff A, Alangaden GJ, Chandrasekar PH. Molecular studies on voriconazole resistance in a clinical isolate of *Aspergillus fumigatus*. In Programs and Abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Illinois, September 14-17, 2003. Abs# M-1250.
44. *Krishnan S, Alangaden GJ, Cutright JL, Manavathu EK, Chandrasekar PH Current Epidemiology of Blood Stream Infections among Cancer Patients, 2000-2002. In Program and abstracts of the 41st Annual Meeting of IDSA, San Diego, 2003. Abs# 378.
45. *Chandrasekar P.H , King R., Dansey R., Mellon-Reppen S., Nareddy S., Akhtar A, Klein J, Abidi M.H, Peres E., Abella E, Alangaden GJ. CMV Infections In Allogeneic Non-Myeloablative Stem Cell Transplant Recipients. In Program and abstracts of the Annual Meeting of American Society for Blood and Marrow Transplantation, Orlando Florida 2004. Biol Blood Marrow Transplant 2004;10:43.
46. *Thyagarajan R, Chandrasekar PH, Haririan A, Morawski K, Gruber SA, Garnick J, El-amm J, West MS, Granger DK, Sillix D, Alangaden GJ. Infectious complications in renal transplant recipients; changing epidemiology in recent years. In Program and abstracts of the 13th International Symposium on Infections in the Immunocompromised Host, Granada, Spain, June 27-30, 2004.
47. *Narreddy, S., Mellon-Reppen, S., Abidi, M.H, Klein, J., Peres, E., Alangaden G., Chandrasekar, P.H. CMV Infections In Allogeneic Non-Myeloablative Stem Cell Transplant Recipients. In Program and abstracts of the 13th International Symposium on Infections in the Immunocompromised Host, Granada, Spain, June 27-30, 2004.
48. *Narreddy, S., Mellon-Reppen, S., Abidi, M.H, Klein, J., Peres, E., Alangaden G., Chandrasekar, P.H. Fungal Infections In Allogeneic Non-Myeloablative Stem Cell Transplant Recipients. In Program and abstracts of the 13th International Symposium on Infections in the Immunocompromised Host, Granada, Spain, June 27-30, 2004.
49. *Alangaden GJ, Thyagarajan R, Morawski K, Gruber SA, Garnick J, El-amm J, West MS, Granger DK, Sillix D, Chandrasekar PH, Haririan A. Changing Epidemiology of Infections in Renal Transplant Recipients; Impact of Current Antimicrobial Prophylaxis and Immunosuppressive Regimens. In Program and abstracts of the 42nd Annual Meeting of the Infectious Diseases Society of America, September 30 – October 3, 2004, Boston. Abstract # 651
50. *Narreddy, S., Mellon-Reppen, S., Abidi, M.H, Klein, J., Peres, E., Alangaden G., Chandrasekar, P.H. Opportunistic Infections In Non-Myeloablative Allogeneic Stem Cell Transplant (NMT) Recipients. In Program and abstracts of the 42nd Annual Meeting of the Infectious Diseases Society of America, September 30 – October 3, 2004, Boston. Abstract #649.

51. Manavathu E, Baskaran I, Alangaden GJ, Akins R, Chandrasekar PH; Effect of Voriconazole on the Expression of Genes Encoding Spore Coat Rodlet Protein (*hyp1*) and Chitin Synthase (*chsE*) in *Aspergillus fumigatus*. In Program and abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy October 30-November 2, 2004, Washington DC Abstract #402292.
52. Manavathu E, Krishnan S, Baskaran I, Alangaden GJ, Chandrasekar PH; A point Mutation in the Cytochrome P450 14 α -Sterol Demethylase Gene *cyp51B* Contributes to Voriconazole Resistance in Laboratory-Selected Isolates of *Aspergillus fumigatus*. In Program and abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy October 30-November 2, 2004, Washington DC Abstract #402780.
53. Flanagan E, Preney K, Robinson P, Alangaden G, Lundstrom T, Ducharme MA, Guzman J, Bander J. Reduction of Intensive Care Unit (ICU) Infections: How Low Can You Go?. In the Program and abstracts of 15th Annual Meeting of the Society for Healthcare Epidemiology of America April 9-12, 2005 Los Angeles CA.
54. Haririan A, Thyagarajan R, Morawski K, Sillix D, El-Amm J, Garnick J, West M, Gruber S, Chandrasekar P, and Alangaden G. Infectious complications after kidney transplantation; risk factors and impact on graft survival. In the program and abstracts of the American Transplant Congress 2005 Meeting, May 21–25, 2005. Seattle, WA. Abstract # 1243.
55. Alangaden GJ, Cutright J, Manavathu E, Krishnan S, Chandrasekar P, Cha R. Efficacy of Cefepime against an extended spectrum beta-lactamase-producing strain of *Escherichia coli* in a murine neutropenic thigh infection model. In Program and abstracts of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy December 16-19, 2005, Washington DC Abstract #B-40-2005.
56. S. Krishnan, P. H. Chandrasekar, G. J. Alangaden, E. K. Manavathu. Molecular Characterization of *Cyp51A* and *B* Genes From Voriconazole-Resistant and -Susceptible Isolates of *Aspergillus Flavus*. In Program and abstracts of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy September 27-30, 2006, San Francisco Abstract #M-1757.
57. S. Krishnan, P. H. Chandrasekar, G. J. Alangaden, E. K. Manavathu. In Vitro Activities of Statins (Anti-Cholesterol Drugs) Alone and in Combination with Antifungal Drugs against *Aspergillus* Species. In Program and abstracts of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy September 27-30, 2006, San Francisco Abstract #M-304.
58. *R. Bhan, A. Kalra, P.H.Chandrasekar, J. Merline, H. Salimnia, , G. J. Alangaden. Epidemiology of non-pertussis *Bordetella* Infections: 5 Year Experience in Immunocompromised Hosts at a Large Medical Center. In Program and abstracts of the 44th Annual Meeting Infectious Diseases Society of America, October 12-15, 2006, Toronto Canada, Abstract #1204.
59. *M. Doshi, J. El-Amm, S. Gruber, D. Sillix, M. West, K. Morawski, P. Chandrasekar, G. J. Alangaden. Current Epidemiology of Symptomatic Urinary Tract Infections (UTIs) in Renal Transplant (RT) Recipients: Emergence of Enterococcus (ENT) as a Significant

- Uropathogen. In Program and abstracts of the 44th Annual Meeting Infectious Diseases Society of America, October 12-15, 2006, Toronto Canada, Abstract #1022.
60. *C-W Chan, P. H. Chandrasekar, G. J. Alangaden, J. Uberti, H. Saliminia. Breakthrough Cytomegalovirus Infection During Valgancyclovir Prophylaxis in Allogeneic Stem Cell Transplant Recipients. In Program and abstracts of the 44th Annual Meeting Infectious Diseases Society of America, October 12-15, 2006, Toronto Canada.
 61. Drew Winston, Jo-Anne van Burik, Vinod Pullarkat, Zenia Papanicolaou, Ravi Vij, Estil Vance, George Alangaden, Roy Chemaly, Finn Bo Petersen, Nelson Chao, Jared Klein, Kellie Sprague, Carolyn Dougherty, Stephen Villano, Michael Boeckh. Prophylaxis against Cytomegalovirus Infections with Oral Maribavir in Allogeneic Stem Cell Transplant Recipients: Results of a Phase 2 Study. In the Program and Abstract of the 48th Annual Meeting of the American Society of Hematology, December 9-12, 2006 Orlando FL. Abstract #1263-200.
 62. W. C. Huskins, H. Wildasin, C. Huckabee, W. Ko, R. Noga, L. Zimmer, M. E. Bradley, J. Jernigan, N. O'Grady, M. Samore, D. Wallace, D. A. Goldmann, the STAR*ICU trial investigators. Adherence to Standard Precautions in Adult Intensive Care Units. In the Proceedings of the 2006 Annual Meeting of the Society for HealthCare Epidemiology of America, March 18-21, 2006, Chicago IL.
 63. Doshi M., J. El-Amm, A. Singh, S. Gruber, M. West, J. Losanoff, S. Migdal, K. Morawski, P. Chandrasekar, G. Alangaden. Symptomatic Urinary Tract Infections in Renal Transplant Recipients: Risk Factors and Current Epidemiology. In the Program and Abstracts of American Transplant Congress, May 5-7, 2007, San Francisco CA.

LECTURES and PRESENTATIONS

Ambulatory Grand Rounds. Out-patient management of HIV positive patients. Wayne State University, Veterans Administration Medical Center, 1992 and 1993.

Pulmonary Grand Rounds. Mechanisms of drug resistance in *Mycobacterium tuberculosis*. Wayne State University, Harper hospital, March, 1994.

Clinico-pathological Conferences. Wayne State University, Veterans Administration Medical Center, July, 1994.

Clinico-pathological Conferences. Wayne State University, Veterans Administration Medical Center, October, 1994.

Emergency Medicine Lecture Series. Community acquired pneumonias. Wayne State University, Detroit Receiving Hospital, March, 1995.

Overview of Tuberculosis. Beyer Hospital, Ypsilanti, MI, May 1995.

Health Maintenance of Patients with HIV. Update on TB and HIV. Wayne State University, Harper Hospital, June 1995.

Pulmonary Grand Rounds. Drug resistance in *M. tuberculosis*. Wayne State University, Harper hospital, January, 1996.

Medicine Grand Rounds. Recent trends in tuberculosis. Hutzel Hospital, January 97.

Wayne State University CME Course. Antibiotic resistance: Prevention, treatment and control. Dearborn Inn, Dearborn, MI, February 28 1997.

USPHS/IDSA/ASBMT Guidelines for the prevention of opportunistic infections in bone marrow transplant patients. Participant in formulation of the draft. Centers for Disease Control and Prevention, Atlanta, Ga, March 19-20, 1997.

Wayne State University and OHEP CME Course. Save 100 Initiatives: Antimicrobial Prescribing. Grace Hospital Grand Rounds, Detroit, MI, October 9 1997.

Centers for Disease Control and Prevention and the Department of Veterans Affairs. Tuberculosis Prevention. Presenter: Section on therapy of tuberculosis. VAMC, Detroit, MI, October 28, 1997.

Urology Grand Rounds. New CDC Guidelines for the management of STDs. Harper Hospital, November 14 1997.

Medicine Grand Rounds. AIDS in India - An Overview. Goa Medical College. Panaji, Goa, India. January 16, 1998.

Physician Assistant Lecture Series 1999. Adult Immunization. Harper Hospital, January 22, 1999.

Physician Assistant Lecture Series 1999. Sexually transmitted diseases. Harper Hospital, January 25, 1999.

Internal Medicine Board Review Course Series 1999. Pneumonias and TB. Harper Hospital, March 16, 1999.

Clinico-pathological Conferences. Wayne State University, Veterans Administration Medical Center, April 28, 1999

Grand Rounds Presentation. Wayne State University, Department of Internal Medicine. "Best Practice Use of Oral Antimicrobial Agents - SAVE 100", Veterans Administration Medical Center, August 25, 1999

Grand Rounds Presentation. Wayne State University, Department of Family Medicine. "Best Practice Use of Oral Antimicrobial Agents - SAVE 100", Grace/ Sinai Hospital, September 14, 1999.

Grand Rounds Division of Pulmonary and Critical Care. Wayne State University. "Advances in Tuberculosis - Applications of molecular biology, December 6, 1999.

Physician Assistant Lecture Series 2000. Infections in immunocompromised hosts. Harper Hospital, January 10, 2000.

Internal medicine Board Review Course Series 2000. MKSAP Review. Detroit Receiving Hospital, January 10, 2000.

Gram-positive infections in cancer patients an emerging problem. Twin City Oncology Club (CME) Meeting. February 10, 2000.

Grand Rounds, Macomb Hospital. April 13th 2000. Management of fungal infections in cancer patients (CME).

Grand Rounds, Macomb Hospital. June 8th 2000. Resistance in Gram-positive pathogens and potential new therapies (CME).

ER Grand Rounds Beaumont Hospital. June 27th 2000. HIV infection and the ER physician (CME).

Grand Rounds, Department of Hematology-Oncology and BMT. Catheter-related infections in cancer patients. St. Louis University, St Louis. July 12th 2000.(CME)

Medicine Grand Rounds. Infections in BMT recipients. Goa Medical College. Panaji, Goa, India. November 23rd 2000.

Medicine Grand Rounds. Fungal Infections in BMT. Tata Memorial Cancer Institute. Parel, Mumbai, India (CME).

ER Grand Rounds Sinai-Grace Hospital. December 14th 2000. HIV infection and the ER physician (CME).

Ambulatory Grand Rounds Department of Internal Medicine. Recent advances in Tuberculosis. April 17th, 2001 (CME)

Infectious Diseases Conference, August 18th, Crystal Mt., MI. Advances in the treatment of viral hepatitis (CME).

Infectious Diseases Conference, August 18th, Crystal Mt., MI. Common viral syndromes (CME).

Ambulatory Grand Rounds Department of Internal Medicine. Approach to infections in the immunocompromised host. October 16th, 2001 (CME).

Medicine Grand Rounds. Infections in patients with cancer. Goa Medical College. Panaji, Goa, India. January 11th 2002.

Internal Medicine Update Conference Update, WSU, Bay Harbor, MI. Diabetic foot infections. (CME).

Internal Medicine Update Conference, WSU, Bay Harbor, MI. Adult immunizations. (CME).

Ambulatory Grand Rounds Department of Internal Medicine. Foot Infections in diabetic patients. October 1, 2002 (CME)

Emergency Department Grand Rounds Beaumont Hospital. HIV infection and the ED physician.

Internal Medicine Grand Rounds. Robert Packard Hospital Sayre PA, December 6, 2002.

Management of fungal infections in high-risk patients. (CME).

Infectious Diseases Symposium. 1st Annual International Medical Society Meeting “Advances in Medicine in the New Millennium”. January 3-5, 2003, Goa India. Approach to patients with pneumonia. (CME).

Infectious Diseases Workshop. 1st Annual International Medical Society Meeting “Advances in Medicine in the New Millennium”. January 3-5, 2003, Goa India. Antimicrobial resistance in Mycobacterium tuberculosis. (CME).

Grand rounds Internal Medicine. Herman Keifer Hospital, Detroit MI. February 20, 2003. Viral hepatitis.

Grand Rounds Internal Medicine. Hospital, Owoso, MI. May 28, 2003. Management of fungal infections. (CME).

Grand Rounds Internal Medicine. Prince Charles Hospital, Louisiana. July 15, 2003. Managing infections in patients with hematological malignancies. (CME).

Infectious Diseases, Lecture. Management of Symptoms in HIV infected patient. Chicago, IL. September 17, 2003. (CME).

Infectious Diseases, Lecture. Management of Symptoms in HIV infected patient. Birmingham, MI. September 17, 2003. (CME).

Internal Medicine Lecture Series. Pontiac Osteopathic Hospital. August 13, 2003. Neutropenic sepsis. (CME).

Infectious Diseases, Lecture. Management of Symptoms in HIV infected patient. Cleveland, OH. September 17, 2003. (CME).

Grand Rounds Internal Medicine. Provena United Samaritans Medical Center, Danville, IL. September 19, 2003. Managing infections in patients with hematological malignancies. (CME).

Internal Medicine. Ambulatory Grand Rounds. Harper Hospital, 2003, Detroit MI. Peer Education Project on Adult Immunization.

Symposium. Michigan Medical Society Annual Meeting, Troy, MI, November 7, 2003. New Antimicrobial Agents. (CME).

Internal Medicine Grand Rounds. St Mary's Hospital. Livonia, MI, December 3, 2003. Management of Infection in patients with malignancies. (CME).

Infectious Diseases Grand Rounds. Henry Ford Hospital, Detroit MI. December 10, 2003. Management of Ventilator-associated pneumonia. (CME).

Symposium, HIV Infection Issues for the Practicing Physician. 2nd Annual International Medical Society Meeting "Healthcare – a Global Perspective". January 2-4, 2004 Florida USA. (CME).

CME Presentation. Emerging Infectious Diseases. 2nd Annual International Medical Society Meeting "Healthcare – a Global Perspective". January 2-4, 2004 Florida USA. (CME).

Internal Medicine Grand rounds. Management of Infections in Cancer Patients. January 6, Tulsa OK (CME).

Resident Lecture Series. Infections in patients with hematologic malignancies. January 20, 2004. Sinai Grace Hospital, Detroit MI.

Lecture Series Renal Transplant Nephrology. CMV Infections in the transplant recipient. February 19, 2004. Harper University Hospital.

Lecture Series in Infectious Diseases. Physician assistants training program. March 8, 2004. Appelbaum Allied Sciences, Detroit MI.

Symposium on Infectious Diseases: Management of febrile neutropenia. March 13, 2004 St John's Hospital, Detroit MI. (CME).

Internal Medicine Grand rounds. Management of infections in patients with hematologic malignancies. March 25 2004, St Vincent's Hospital Cleveland, OH. (CME).

Internal Medicine Grand rounds. Update on immunization. March 29, 2004, Botsford Hospital, Detroit MI. (CME).

Internal Medicine Grand rounds. Management of infections in patients with malignancies. April 14, 2004, Robinson Memorial Hospital, Ravenna OH. (CME).

Internal Medicine Grand rounds. Management of infections in cancer patients with neutropenia. April 20, 2004, Crittendon Hospital, Rochester MI. (CME).

Infectious Diseases Update: Emerging respiratory infections. Association of Kerala Medical Graduates (AKMG) Silver Jubilee CME Program. July 16, 2004 Dearborn MI (CME).

Internal Medicine Grand rounds. Approach to Infections in the Immunocompromised Host. August 19, 2004, Goa Medical College, Goa India.

Infectious Diseases Update for the Practicing Physician - Tuberculosis. September 22, 2004 Providence Hospital, Southfield MI (CME).

Internal Medicine Resident Lecture Series, Tuberculosis, Detroit Hospital, August 18, 2005.

Adult Immunization Lecture. Eugene Applebaum College of Pharmacy, WSU February 17, 2005. (CME)

Lecture Series in Infectious Diseases. Infections in Immunocompromised Hosts. Physician assistants training program, Appelbaum Allied Sciences WSU, Detroit MI, March 7, 2005.

Vascular Surgery Rounds ESBLs and clinical significance. University Hospitals of Cleveland March 8, 2005.

Invited Lecture, Facility acquired pneumonia. Michigan Society of Infection Control Annual Spring Meeting, Lansing, March 15, 2005. (CME)

Invited lecture, Mathematics and Medicine, Indus Center of Academic Excellence, 10th Anniversary Banquet, Farmington, MI, March 19, 2005.

Internal Medicine, Resident Lecture Series, Meningitis Harper Hospital, August 18, 2005.

Immunization update. Henry Ford Medical Group, Sterling Heights MI, September 15, 2005. (CME)

Moderator, Roundtable Conference Fungal Infections, Tampa, Florida, October 20, 2005.(CME).

Ambulatory Grand rounds. Approach to Infections in Immunocompromised Hosts. Harper Hospital, November 15, 2005. (CME).

Immunization update. Henry Ford Medical Group, Sterling Heights MI, September 15, 2005. (CME)

Grand Rounds, Battle Creek Health System, Current Management of Fungal Infections. Battle Creek MI, June 16, 2006 (CME)

Grand Rounds St Mary's Hospital, Case Studies in Fungal Infections. July 7, 2006, Livonia MI. (CME).

Symposium. Annual Meeting Wayne State University School of Pharmacy. Update on Fungal Infections. September 2006, Detroit MI (CME).

Symposium. Michigan Medical Society Annual Meeting, What's New in Infectious Diseases? October 26, 2006. Troy, MI. (CME).

Grand Rounds, Family Medicine. New Vaccines and Immunization update. November 26, 2006. Bon Secour Hospital Grosse Pointe MI. (CME).

Symposium (via videoconference). Critical Care International Conference. Recent Advances in the Diagnosis and management of Tuberculosis. King Faisal Hospital, Saudia Arabia May 7, 2007.

Ambulatory Grand Rounds Wayne State University. Newer Vaccines and Adult Vaccination. May 15, 2007. Detroit, MI. (CME).

Grand Rounds, Goa Medical College, Recent Advances in Tuberculosis. July 12, 2007. Goa Medical College Panaji, Goa India.